A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Abstract

In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexamethasone 40/20 mg/day (cycles 1-4) and 20/10 mg/day (cycles 5-8) (days of/after bortezomib dosing… (More)
DOI: 10.1182/blood-2013-07-517276

Topics

6 Figures and Tables

Cite this paper

@article{Richardson2014AP2, title={A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.}, author={Paul G Richardson and Wanling Xie and Sundar Jagannath and Andrzej Jakubowiak and Sagar Lonial and Noopur S. Raje and Melissa Alsina and Irene M Ghobrial and Robert L. Schlossman and Nikhil C. Munshi and Amitabha Mazumder and David H. Vesole and Jonathan L. Kaufman and Kathleen Colson and Mary L McKenney and Laura E. Lunde and John Feather and Michelle E. Maglio and Diane L Warren and Dixil Francis and Teru Hideshima and Robert D. Knight and D. W. Esseltine and Constantine Mitsiades and Edie A. Weller and Kenneth C. Anderson}, journal={Blood}, year={2014}, volume={123 10}, pages={1461-9} }